A team in South Korea has developed a method that can increase sensitivity when paired with surface-enhanced Raman spectroscopy.
The award comes after the company received $5.5 million from the agency last year to support the research, development, and increased production of the test.
In PLOS this week: statistical genetic variant clustering method, microbiome analysis of urinary tract infections, and more.
IndyGeneUS plans to sequence 2 million samples for the Aurum Institute's biorepository, applying multiple next-generation DNA sequencing methods.
CMS has issued a new billing policy and will no longer reimburse for the use of Interpace's ThyGeNext and ThyraMir thyroid cancer tests under certain conditions.
Last week, GenomeWeb's readers were most interested in the use of nanopore sequencing for rapidly diagnosing genetic disorders.
The Austrian DNA synthesis company said it will use the funds to build production facilities, prepare to enter the US market, and hire new staff.
Newly merged with a firm founded by BioFire Diagnostics alums, Co-Diagnostics plans to develop small panels for the system with up to six targets.
The hydrogel-based benchtop kit, called Asteria, enables a simple library preparation workflow with integrated data analytics.
The process control contains 43 intact, inactivated bacteria, yeasts, and antimicrobial resistance targets to validate the syndromic PCR sepsis panel.
New, highly sensitive proteomics platforms could discover new content for use in the company's assays, but they could also cut into its business.
With single-cell RNA sequencing, researchers characterized expression and cell type shifts in brain vascular samples from individuals with or without brain arteriovenous malformations.
Meridian Bioscience has launched two new master mixes to detect DNA and RNA in crude saliva samples: its Lyo-Ready Direct DNA qPCR Saliva Mix and its Lyo-Ready Direct RNA/DNA qPCR Saliva Mix. Both mixes can be used in liquid format or lyophilized and are optimized for use on crudely processed saliva or sputum samples for improved assay sensitivity and flexible protocols. No further optimization is needed beyond the addition of primers and probes.
Interpace Biosciences has appointed Vijay Aggarwal to its board of directors, effective Feb. 1. Aggarwal is currently managing partner of life sciences strategic advisory company The Channel Group. He previously served as CEO of Vaxigenix, a pharmaceutical company developing treatments for colorectal cancer. He was also president and CEO of predictive pathology company Aureon Laboratories, which offered advanced tissue analysis services to physicians and the pharma industry. Aggarwal also served as president of Quest Diagnostics Ventures, where he was responsible for new technology, new business models, clinical trials testing, and direct-to-consumer strategies. He also held a variety of positions earlier in his career at SmithKline Beecham Clinical Laboratories, including EVP of laboratories and VP of managed care.
Researchers spelled out relationships between germline variants in nine breast cancer susceptibility genes and tumor features ranging from molecular subtype to size.